No Data
No Data
BrainStorm Cell Therapeutics Updates On NurOwn Stem Cell Therapy For ALS
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
Express News | Brainstorm Cell Therapeutics Inc Says on July 18, Co Received Mvls Deficiency Notice From the Listing Qualifications Department Staff of Nasdaq
Maxim Group Upgrades Brainstorm Cell Therapeutics(BCLI.US) to Buy Rating, Announces Target Price $2
Maxim Group analyst Jason McCarthy upgrades $Brainstorm Cell Therapeutics(BCLI.US)$ to a buy rating, and sets the target price at $2.According to TipRanks data, the analyst has a success rate of 24.0%
Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial
Brainstorm Cell Therptcs Price Target Announced at $2.00/Share by Maxim Group
No Data